Compugen Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN), a clinical-stage drug discovery and development company founded in 1993 and headquartered in Holon, Israel, with additional operations in the United States and Europe, utilizes a predictive computational discovery platform to identify novel drug targets and biological pathways for developing therapeutics focused on cancer immunotherapy. The company's immuno-oncology pipeline features clinical-stage programs including COM701, a potential first-in-class anti-PVRIG antibody evaluated in Phase 1 trials as monotherapy and in combinations with PD-1 inhibitors and/or TIGIT antibodies for advanced solid tumors; COM902, a potential best-in-class anti-TIGIT antibody also in Phase 1 for solid and hematological tumors as monotherapy and in combination with COM701; and bapotulimab, a collaborative program targeting another immune checkpoint; alongside early preclinical candidates addressing mechanisms of immune resistance such as myeloid targets and COM503, a high-affinity antibody blocking IL-18 binding protein interactions. Recent developments include ongoing Phase 1 data readouts and combination trial advancements for its proprietary assets, strategic partnerships with AstraZeneca and Gilead Sciences providing milestone payments and royalties, a strengthened cash position of approximately $94 million supporting operations into 2027, and a leadership transition with Eran Ophir assuming the role of President and CEO while Anat Cohen-Dayag moves to Executive Chairperson.
Compugen to Participate in BTIG Biotechnology Conference 2026
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Q1 Earnings Call Highlights
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen Reports First Quarter 2026 Results
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Compugen Q4 Earnings Call Highlights
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
Compugen Reports Fourth Quarter and Full Year 2025 Results
Compugen to Participate in Upcoming Investor Conferences